ACOX2 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q99424 |
---|---|
Clone Names | 100603291 |
Gene ID | 8309 |
---|---|
Other Names | Peroxisomal acyl-coenzyme A oxidase 2, 3-alpha, 7-alpha, 12-alpha-trihydroxy-5-beta-cholestanoyl-CoA 24-hydroxylase, 3-alpha, 7-alpha, 12-alpha-trihydroxy-5-beta-cholestanoyl-CoA oxidase, Trihydroxycoprostanoyl-CoA oxidase, THCA-CoA oxidase, THCCox, ACOX2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ACOX2 (HGNC:120) |
---|---|
Function | Oxidizes the CoA esters of the bile acid intermediates di- and tri-hydroxycholestanoic acids (PubMed:27884763). Capable of oxidizing short as well as long chain 2-methyl branched fatty acids (By similarity). |
Cellular Location | Peroxisome |
Tissue Location | Present in all tissues tested: heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Most abundant in heart, liver and kidney. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The product of this gene belongs to the acyl-CoA oxidasefamily. It encodes the branched-chain acyl-CoA oxidase which isinvolved in the degradation of long branched fatty acids and bileacid intermediates in peroxisomes. Deficiency of this enzymeresults in the accumulation of branched fatty acids and bile acidintermediates, and may lead to Zellweger syndrome, severe mentalretardation, and death in children.
References
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Rikova, K., et al. Cell 131(6):1190-1203(2007)Wanders, R.J., et al. Annu. Rev. Biochem. 75, 295-332 (2006) :Moghrabi, N.N., et al. Biochem. Biophys. Res. Commun. 231(3):767-769(1997)Baumgart, E., et al. Ann. N. Y. Acad. Sci. 804, 678-679 (1996) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.